OmniAb, Inc. (NASDAQ:OABI) Insider Sells $30,231.20 in Stock

OmniAb, Inc. (NASDAQ:OABI) insider Charles S. Berkman sold 8,215 shares of OmniAb stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total value of $30,231.20. Following the sale, the insider now directly owns 364,131 shares in the company, valued at approximately $1,340,002.08. The trade was a 2.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

OmniAb Trading Up 0.3 %

OmniAb stock traded up $0.01 during mid-day trading on Wednesday, reaching $3.67. The company’s stock had a trading volume of 294,723 shares, compared to its average volume of 489,354. OmniAb, Inc. has a twelve month low of $3.10 and a twelve month high of $6.55. The business has a 50 day moving average price of $3.49 and a 200-day moving average price of $3.91. The firm has a market cap of $518.28 million, a price-to-earnings ratio of -5.92 and a beta of -0.12.

Analyst Ratings Changes

OABI has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th. Benchmark reiterated a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research note on Thursday, November 14th.

Institutional Investors Weigh In On OmniAb

Institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC raised its position in shares of OmniAb by 1.1% during the 4th quarter. Janus Henderson Group PLC now owns 7,960,321 shares of the company’s stock worth $28,179,000 after purchasing an additional 88,993 shares during the period. Dimensional Fund Advisors LP lifted its stake in OmniAb by 4.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,025,674 shares of the company’s stock valued at $10,711,000 after buying an additional 142,513 shares during the last quarter. Rice Hall James & Associates LLC boosted its holdings in shares of OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock valued at $11,515,000 after acquiring an additional 163,038 shares during the period. Geode Capital Management LLC grew its position in shares of OmniAb by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 2,353,442 shares of the company’s stock worth $8,333,000 after acquiring an additional 28,061 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of OmniAb by 1.7% in the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company’s stock worth $8,594,000 after acquiring an additional 34,654 shares during the period. Institutional investors and hedge funds own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.